3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
3
Urinary Bladder Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Small Cell Lung Carcinoma
1
Liver Neoplasms
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Interventions
pembrolizumab
14
Paclitaxel
13
Carboplatin
12
Bevacizumab
7
Specimen Handling
6
Cisplatin
6
olaparib
5
Taxes
5
Fulvestrant
5
Nivolumab
4
Megestrol Acetate
4
Magnetic Resonance Spectroscopy
4
Biopsy
4
palbociclib
3
durvalumab
3
Oxaliplatin
3
Leucovorin
3
Letrozole
3
Immunoglobulin G
3
Fluorouracil
3
Doxorubicin
3
Docetaxel
3
Disulfides
3
trastuzumab deruxtecan
2
ribociclib
2
pertuzumab
2
lenvatinib
2
ipatasertib
2
dostarlimab
2
capivasertib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
tremelimumab
×
30 days
×
Clear all
NCT06680739
2026-06-01
SERPENTINE
Vall d'Hebron Institute of Oncology
Phase 2
Recruiting
60 enrolled